Table 3.
Change in Clinical Indices With Liver Fibrosis Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease
| Change in Parameter | Fibrosis Progression (n = 9) | No Fibrosis Progression (n = 15) | P Value |
|---|---|---|---|
| Change in HIV-related indices | |||
| CD4 count, cells/μL | −37 ± 124 | −37 ± 117 | > .99 |
| Log HIV RNA load | −0.04 ± 0.66 | −0.02 ± 0.87 | .95 |
| Change in immunologic indices | |||
| CRP, mg/L | 4.0 ± 5.4 | −0.2 ± 2.4 | .02 |
| IL-6, pg/mL | −0.1 ± 3.0 | −0.2 ± 1.3 | .91 |
| Change in hepatic indices | |||
| Liver fat, % | 0.8 ± 4.3 | −0.3 ± 4.3 | .54 |
| NAS | 1.1 ± 0.8 | −0.5 ± 0.6 | < .0001 |
| Lobular inflammation | 0.4 ± 0.5 | −0.2 ± 0.4 | .003 |
| Hepatocellular ballooning | 0.4 ± 0.5 | −0.2 ± 0.6 | .01 |
| ALT, U/L | 13 ± 19 | 1 ± 10 | .08 |
| AST, U/L | 6 ± 18 | −7 ± 20 | .13 |
| FIB-4 | 0.12 ± 0.40 | −0.20 ± 0.47 | .12 |
| Change in metabolic indices | |||
| BMI, kg/m2 | 0 ± 1 | 0 ± 1 | .81 |
| Waist circumference, cm | 1 ± 3 | 1 ± 3 | .83 |
| Visceral fat, cm2 | 15 ± 53 | 11 ± 33 | .83 |
| Subcutaneous fat, cm2 | 27 ± 55 | 12 ± 37 | .46 |
| Fasting glucose, mg/dL | 7 ± 13 | 4 ± 12 | .48 |
| HbA1c, % | 0.3 ± 0.4 | −0.1 ± 0.3 | .02 |
| Triglycerides, mg/dL | −11 ± 46 | −1 ± 53 | .64 |
Variables are expressed as mean ± standard deviation. Bold text denotes statistical significance with P < .05.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; FIB-4, Fibrosis-4 Index for Liver Fibrosis; HbA1c, hemoglobin A1c; HIV, human immunodeficiency virus; IL-6, interleukin 6; NAS, Nonalcoholic Fatty Liver Disease Activity Score.